Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-β-D-1′,3′-dioxolan guanine

Antiviral Research

Volumn 66, Issue 2-3, 2005, Pages 153-158

  Feng, Joy Y ^a   Myrick, Florence ^a   Selmi, Boulbaba ^b   Deval, Jérôme ^b   Canard, Bruno ^b   Borroto Esoda, Katyna ^a  

^a GILEAD SCIENCES INC   (United States)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Amdoxovir; DAPD; DXG; HIV 1 reverse transcriptase; Multi drug resistance; Pre steady state; Q151M

Indexed keywords

ABACAVIR; BETA DEXTRO 1',3' DIOXOLAN GUANINE; DEOXYGUANOSINE TRIPHOSPHATE; DIDANOSINE; GUANINE DERIVATIVE; LAMIVUDINE; MUTANT PROTEIN; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SYNTHESIS; ENZYMATIC ASSAY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STEADY STATE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

AMINO ACID SUBSTITUTION; DIOXOLANES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; GLUTAMINE; GUANOSINE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; METHIONINE; MUTAGENESIS, SITE-DIRECTED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 19344365422     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.03.001     Document Type: Article

References (30)

1. H.Z. Bazmi, J.L. Hammond, S.C.H. Cavalcanti, C.K. Chu, R.F. Schinazi, and J.W. Mellors In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-d-dioxolane-guanosine and suppress resistance to 3′-azido- 3′-deoxythymidine Antimicrob. Agents Chemother. 44 2000 1783 1788
2. J.W. Beach Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions Clin. Ther. 20 1998 2 25
3. J. Boretto, S. Longhi, J.-M. Navarro, B. Selmi, J. Sire, and B. Canard An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase Anal. Biochem. 292 2001 139 147
4. J. Deval, B. Selmi, J. Boretto, M.P. Egloff, C. Guerreiro, S. Sarfati, and B. Canard The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using α-boranophosphate nucleotide analogues J. Biol. Chem. 277 2002 42097 42104
5. J. Deval, K.L. White, M.D. Miller, N.T. Parkin, J. Courcambeck, P. Halfon, B. Selmi, J. Boretto, and B. Canard Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations J. Biol. Chem. 279 2004 509 516
6. J.Y. Feng, and K.S. Anderson Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase Biochemistry 38 1999 55 63
7. P.A. Furman, J. Jeffrey, L. Kiefer, J.Y. Feng, K.S. Anderson, K. Borroto-Esoda, E. Hill, W.C. Copeland, C.K. Chu, J.-P. Sommadossi, I. Liberman, R.F. Schinazi, and G.R. Painter Mechanism of action of 1-β-d-2,6- diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-d-dioxolane guanosine Antimicrob. Agents Chemother. 45 2001 158 165
8. J.G. Garcia-Lerma, R.F. Schinazi, A.S. Juodawlkis, V. Soriano, Y. Lin, K. Tatti, D. Rimland, T.M. Folks, and W. Heneine A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type1 to lamivudine (3TC) Antimicrob. Agents Chemother. 43 1999 264 270
9. Z. Gu, M.A. Wainberg, N. Nguyen-Ba, L. L'Heureux, J.-M. de Muys, T.L. Bowlin, and R.F. Rando Mechanism of action and in vitro activity of 1′,3′-dioxolanypurine nucleoside analogs against sensitive and drug-resistant human immunodeficiency virus type 1 variants Antimicrob. Agents Chemother. 43 1999 2376 2382
10. D.C. Harris Experimental error J. Fiorillo Quantitative Chemical Analysis 1995 W.H. Freeman and Company New York
11. A.K. Iversen, R.W. Shafer, K. Wehrly, M.A. Winters, J.I. Mullins, B. Chesebro, and T.C. Merigan Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy J. Virol. 70 1996 1086 1090
12. J.L. Jeffrey, J.Y. Feng, C.C.R. Qi, K.S. Anderson, and P.A. Furman Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state analyses J. Biol. Chem. 278 2003 18971 18979
13. W.M. Kati, K.A. Johnson, L.F. Jerva, and K.S. Anderson Mechanism and fidelity of HIV reverse transcriptase J. Biol. Chem. 267 1992 25988 25997
14. M.F. Kavlick, K. Wyvill, R. Yarchoan, and H. Mitsuya Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy J. Infect. Dis. 177 1998 1506 1513
15. P. Kosalaraksa, M.F. Kavlick, V. Maroun, R. Le, and H. Mitsuya Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay J. Virol. 73 1999 5356 5363
16. Y. Maeda, D.J. Venzon, and H. Mitsuya Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance J. Infect. Dis. 177 1998 1207 1213
17. D.J. McColl, and M.D. Miller The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1 J. Antimicrob. Chemother. 51 2003 219 223
18. J.P. Mewshaw, F.T. Myrick, D.A. Wakefield, B.J. Hooper, J.L. Harris, B. McCreedy, and K. Borroto-Esoda Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails J. Acquir. Immune Defic. Syndr. 29 2002 11 20
19. D. Pillay, S. Taylor, and D.D. Richman Incidence and impact of resistance against approved antiretroviral drugs Rev. Med. Virol. 10 2000 231 253
20. J.-C. Schmit, J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.-M. Vandamme Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain J. Infect. Dis. 174 1996 962 968
21. J.-C. Schmit, K. Van Laethem, L. Ruiz, P. Hermans, S. Sprecher, A. Sonnerborg, M. Leal, T. Harrer, B. Clotet, V. Arendt, E. Lissen, M. Witvrouw, J. Desmyter, E. De Clercq, and A.-M. Vandamme Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries AIDS 12 1998 2007 2015
22. R.W. Shafer, M.J. Kozal, M.A. Winters, A.K. Iversen, D.A. Katzenstein, M.V. Ragni, W.A. Meyer, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T.C. Merigan Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations J. Infect. Dis. 169 1994 722 729
23. R.W. Shafer, A.K. Iversen, M.A. Winters, E. Aguiniga, D.A. Katzenstein, and T.C. Merigan Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy J. Infect. Dis. 172 1995 70 78
24. C. Shi, and J.W. Mellors A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors Antimicrob. Agents Chemother. 41 1997 2781 2785
25. T. Shirasaka, R. Yarchoan, M.C. O'Brien, R.N. Husson, B.D. Anderson, E. Kojima, T. Shimada, S. Broder, and H. Mitsuya Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study Proc. Natl. Acad. Sci. U.S.A. 90 1993 562 566
26. T. Shirasaka, M.F. Kavlick, T. Ueno, W.Y. Gao, E. Kojima, M.L. Alcaide, S. Chokekijchai, B.M. Roy, E. Arnold, and R. Yarchoan Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleoside Proc. Natl. Acad. Sci. U.S.A. 92 1995 2398 2402
27. D.S. Stein, and K.H.P. Moore Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians Pharmacotherapy 21 2001 11 34
28. T. Ueno, and H. Mitsuya Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay Biochemistry 36 1997 1092 1099
29. T. Ueno, T. Shirasaka, and H. Mitsuya Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates J. Biol. Chem. 270 1995 23605 23611
30. O.S. Weislow, R. Kiser, D.L. Fine, J. Bader, R.H. Shoemaker, and M.R. Boyd New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity J. Natl. Cancer Inst. 81 1989 577 586